Baixas Taxas de Progressão Radiográfica Associadas com Eficácia Clínica em até 2 anos de Seguimento Após Tratamento com Guselkumab: Resultados de um Ensaio Clínico Randomizado de Fase 3, Duplo-Cego, Controlado com Placebo com Pacientes Naïve a Biológicos com Artrite Psoriásica Ativa
RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789
Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.
Data also highlight the importance of addressing structural damage in a timely manner to optimise long-term patient outcomes, including preservation of function.
Keywords:
